Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$51.20 USD

51.20
1,551,333

+0.77 (1.53%)

Updated Jul 24, 2024 04:00 PM ET

After-Market: $51.22 +0.02 (0.04%) 5:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 26% (186 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Arpita Dutt headshot

The FDA Approved Fewer Drugs in 2016: Here's Why

Was there any specific reason for the significantly lower number of drug approvals in 2016 compared to 2015?

    Impax (IPXL) Applies for Generic Aubagio; Sanofi Files Lawsuit

    Impax Laboratories, Inc. (IPXL) announced that it has filed an Abbreviated New Drug application (ANDA) with the FDA for a generic version of Sanofi's Aubagio (teriflunomide) tablets, 14 mg.

      Amgen's Repatha Wins Over Sanofi & Regeneron's Praluent

      The U.S. District Court in Delaware granted Amgen, Inc. (AMGN) permanent injunction against infringement by Sanofi and Regeneron of two patents owned by the former for Repatha.

        Arpita Dutt headshot

        Pharma Stock Roundup: PCSK9 Inhibitor Praluent in News, Allergan's Preliminary 2017 View

        Key highlights this week include a court injunction blocking sales of PCSK9 inhibitor Praluent and preliminary guidance from Allergan (AGN).

          Eli Lilly Acquires Boehringer Ingelheim's Pet Vaccines Unit

          Eli Lilly and Company's (LLY) animal health subsidiary Elanco, announced that it has closed the previously announced acquisition of German drugmaker Boehringer Ingelheim's Vetmedica U.S. pet vaccines unit.

            Sanofi (SNY) Closes Business Exchange Deal with Boehringer

            Sanofi (SNY) announced the closing of a previously announced deal to exchange its Merial animal health business with Boehringer Ingelheim's consumer healthcare (CHC) segment. The transaction was signed in Jun 2016.

              VIVUS (VVUS): Will Qsymia & Stendra Sales Improve in 2017?

              On Jan 3, we issued an updated report on VIVUS, Inc. (VVUS).

                Arpita Dutt headshot

                Regeneron vs. Vertex: Which Stock is a Better Pick?

                Both Regeneron (REGN) and Vertex look set for a rebound in 2017 after a tough and challenging 2016.

                  J&J Resumes Talks with Actelion: Did Sanofi Just Lose Out?

                  In an interesting turn of events, Johnson & Johnson (JNJ) announced that it is once again discussing a possible transaction with Swiss biotechnology company Actelion Ltd. (ALIOF).

                    Arpita Dutt headshot

                    Pharma Stock Roundup: Lilly Up on Guidance, Merck Awarded $2.54B in HCV Case

                    Lilly (LLY) was among the biggest gainers among major pharma stocks last week with the company providing better-than-expected guidance for 2017.

                      Lilly Stock Surges on Robust 2017 View; Launches Basaglar

                      Eli Lilly and Company (LLY) issued a better-than-expected financial guidance for 2017, alleviating investor concern to a large extent.

                        J&J (JNJ) Ends Deal Talks with Actelion: Will Sanofi Gain?

                        On Tuesday, Johnson & Johnson (JNJ) announced that it has ended talks regarding a possible transaction with Swiss biotechnology company, Actelion Ltd. (ALIOF), reportedly for a disagreement over the purchase price.

                          Arpita Dutt headshot

                          Pharma Stock Roundup: Drug Pricing Heat Back on Sector, Endo, Mylan, AZN to Cut Jobs

                          Drug pricing is back in focus with president-elect Trump making it clear that he does not like price increases.

                            Novo Nordisk Files Regulatory Application for Semaglutide

                            Novo Nordisk (NVO) submitted regulatory application for semaglutide in both the U.S. and the EU for the treatment of adults with type II diabetes.

                              Alnylam Reports Positive Data on Fitusiran, Givosiran

                              Alnylam (ALNY) announced new positive data from an ongoing phase II OLE study on fitusiran for the treatment of patients with hemophilia A or B, without inhibitors.

                                Novo Nordisk's Tresiba Shows Safe Cardiovascular Profile

                                Novo Nordisk (NVO) announced headline results from the DEVOTE study that confirmed the cardiovascular safety of Tresiba, in comparison to Sanofi???s (SNY) Lantus.

                                  The Zacks Analyst Blog Highlights: UnitedHealth, 21st Century Fox, Sanofi, MasterCard and Barclays

                                  The Zacks Analyst Blog Highlights: UnitedHealth, 21st Century Fox, Sanofi, MasterCard and Barclays

                                    Arpita Dutt headshot

                                    Celgene vs. Regeneron: Which Stock is a Better Pick?

                                    Both Celgene (CELG) and Regeneron (REGN) are Zacks Rank #2 (Buy) stocks; which one of these two stocks is a better choice for investors?

                                      Arpita Dutt headshot

                                      Pharma Industry Outlook: Pricing Pressure and M&As in Focus

                                      According to a tracking poll, most Americans (72%) find drug costs unreasonable and 74% are of the view that drug companies put profits before people.

                                        Arpita Dutt headshot

                                        Pharma Industry Outlook: Pricing Pressure and M&As in Focus

                                        According to a tracking poll, most Americans (72%) find drug costs unreasonable and 74% are of the view that drug companies put profits before people.

                                          Arpita Dutt headshot

                                          Pharma Stock Outlook - July 2015

                                          Mergers, acquisitions and deals continue to take center-stage in the pharma sector. While 2014 turned out to be one of the most active years in the pharma sector where mergers and acquisitions and licensing agreements are concerned, the trend continues this year as well.

                                            Arpita Dutt headshot

                                            Pharma Stock Outlook - July 2015

                                            Mergers, acquisitions and deals continue to take center-stage in the pharma sector. While 2014 turned out to be one of the most active years in the pharma sector where mergers and acquisitions and licensing agreements are concerned, the trend continues this year as well.